Pioneering Precision Radiotherapy & Chemotherapy
Improves specificity of radiochemotherapy with localized action minimizes side effects
Switching on prodrugs using radiotherapy.
Nature Chemistry 2021; 13(8) : 805-810.
PolyAdvant Pharmaceutical is at the forefront of transforming cancer treatment through precision radiochemotherapy. Our approach leverages the synergy between radiation and prodrugs to enhance the efficacy of cancer treatment while minimizing toxicity.
The currently developed drugs,
XP-102 and XPADC-106
The primary applications of XP-102 and XPADC-106 are in curative radiotherapy and neoadjuvant radiotherapy.
The main types of cancers targeted include lung cancer, rectal cancer, oesophageal cancer, cervical cancer, endometrial cancer, prostate cancer, head and neck cancer, pancreatic cancer, glioblastoma, and soft tissue sarcomas.
Targeted Development of XP-102 for Pancreatic Cancer and HNSCC
Pancreatic cancer
Head and neck cancer